AC Immune Beefs Up Neurodegenerative Pipeline With AFFiRiS Alpha-Synuclein Portfolio
Deal Snapshot: The company is looking to expand its pipeline beyond Alzheimer’s, where it hit a speedbump in September with the failure of a tau-targeting drug.
You may also be interested in...
The US FDA lifted a clinical hold that it had placed in November after reviewing the company’s INDs to start Phase IIa studies in MSA and Parkinson’s, which was the subject of a hold lifted in January.
With a broad pipeline focused on neurodegenerative disease, AC Immune is about to begin a Phase II program investigating an alpha-synuclein-targeted peptide vaccine with a diagnostic to stratify patients.
Novartis and Roche may be committed to the target, but AbbVie has decided that its efforts in Parkinson's will not include a Phase II trial of its Swedish partner's alpha synuclein drug.